American Renal Associates Holdings Inc. (NYSE:ARA) shares dropped 1.7% during trading on Thursday . The company traded as low as $26.05 and last traded at $26.35, with a volume of 77,471 shares changing hands. The stock had previously closed at $26.80.

ARA has been the topic of a number of research reports. SunTrust Banks Inc. initiated coverage on shares of American Renal Associates Holdings in a research report on Monday, May 16th. They set a “buy” rating and a $34.00 target price on the stock. Goldman Sachs Group Inc. initiated coverage on shares of American Renal Associates Holdings in a research report on Monday, May 16th. They set a “neutral” rating and a $30.00 target price on the stock. Leerink Swann reissued an “outperform” rating on shares of American Renal Associates Holdings in a research report on Monday, May 16th. Wells Fargo & Co. initiated coverage on shares of American Renal Associates Holdings in a research report on Monday, May 16th. They issued an “outperform” rating on the stock. Finally, Barclays PLC initiated coverage on shares of American Renal Associates Holdings in a research report on Monday, May 16th. They issued an “overweight” rating and a $33.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $32.50.

The stock has a market cap of $576.81 million and a PE ratio of 13.22. The stock has a 50-day moving average price of $0.00 and a 200 day moving average price of $0.00.

American Renal Associates Holdings (NYSE:ARA) last posted its earnings results on Thursday, May 12th. The company reported $0.16 EPS for the quarter. The company earned $172.10 million during the quarter, compared to analyst estimates of $149.30 million. On average, analysts forecast that American Renal Associates Holdings Inc. will post $0.88 earnings per share for the current year.

American Renal Associates Holdings, Inc is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.